Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19
NCT07196306 · BayCare Health System · PHASE2 · withdrawn · last registry update 2025-09-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no participants enrolled” | – | Registry record, BayCare Health System |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), tocilizumab + Placebo (NCT03644667)
- 2026-08-20Also stopped (terminated): University Hospital, Strasbourg, France, a drug against IL6R (NCT02246140)
- 2026-08-18Results posted on the registry: Hoffmann-La Roche, Glofitamab + Tocilizumab (NCT04980222)
- 2026-08-12Results posted on the registry: Hoffmann-La Roche, Satralizumab + Placebo (NCT06106828)
- 2026-08-07Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Tocilizumab (NCT04729959)
- 2026-08-03Results posted on the registry: Columbia University, Rituximab + Tocilizumab (NCT04375228)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-31Results posted on the registry: Hoffmann-La Roche, Satralizumab + Placebo (NCT05987423)
- 2026-06-08Also stopped (terminated): University of Chicago, Tocilizumab + Tocilizumab (NCT04479358)
- 2026-05-26Results posted on the registry: Memorial Sloan Kettering Cancer Center, Cyclosporine + Mycophenolate Mofetil (NCT03434730)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-06Phase 3 first posted: Merck Sharp & Dohme LLC, MK-1045 + Blinatumomab (NCT07570173)
- 2026-04-03Phase 3 first posted: Capital Medical University, Tocilizumab + Placebo (NCT07509645)
- 2026-03-06Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2026-02-10Also stopped (terminated): Queen's Medical Center, Tocilizumab + Placebo (NCT04412772)
- 2026-01-22Results posted on the registry: Takeda, TAK-500 + Pembrolizumab (NCT05070247)
- 2026-01-22Also stopped (terminated): Takeda, TAK-500 + Pembrolizumab (NCT05070247)
- 2026-01-13Phase 3 first posted: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, BMS-986353 + Fludarabine (NCT07335562)
- 2025-12-16Phase 3 first posted: Sanofi, Sarilumab + Sarilumab (NCT07286214)
- 2025-12-15Phase 3 first posted: Yale University, Anakinra + Tocilizumab (NCT07281027)
- 2025-12-04Phase 3 first posted: Capital Medical University, Tocilizumab + Placebo (NCT07263776)
- 2025-11-21Results posted on the registry: Hoffmann-La Roche, Nab-Paclitaxel + Gemcitabine (NCT03193190)
- 2025-11-13Also stopped (suspended): Massachusetts General Hospital, Tocilizumab + Placebo (NCT03787290)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision